<DOC>
	<DOCNO>NCT00413075</DOCNO>
	<brief_summary>This Phase I dose escalation study PXD101 administer orally . Oral belinostat give twice daily various dose schedule patient solid tumor . Doses escalate maximum tolerate dose ( MTD ) identify . In parallel , cohort lymphoma patient give oral belinostat discontinuous daily dose schedule .</brief_summary>
	<brief_title>Study Oral PXD101 Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<criteria>Inclusion Criteria Inclusion criterion must meet time screen unless otherwise specify . Age ≥ 18 year Solid Tumor : Histologically document diagnosis primary metastatic solid tumor refractory standard therapy standard therapy exist . Entry include , limited patient androgenindependent prostate cancer , cancer breast , ovary , head neck , nonsmall cell lung , bladder , colorectal kidney . Lymphoma : Relapsed refractory BCell , TCell NKCell lymphoma Hodgkin 's Disease . At Yale Cancer Center , lymphoma patient limit eligible potentially curative reinduction regimen transplant without reasonable chance durable remission standard therapy . At least one evaluable lesion . Lesions must evaluate CTscan , MRI , bone scan . Patients prostate cancer , bone disease rise PSA evaluable disease eligible evaluate base PSA . For lymphoma patient , lesion also measure PET and/or evaluate peripheral blood bone marrow . Progressive disease : Progressive disease define new progressive lesion CTscan , MRI , bone scan rise PSA ( see Section 11.3 ) . ≥ 4 week since prior RT chemotherapy . Karnofsky Performance Status ≥ 60 % Solid Tumor : Acceptable liver , renal bone marrow function include follow : Absolute neutrophil count ≥ 1.5 x 109/L Hemoglobin ≥ 9.0 g/dl Platelets ≥ 100 x 109/L Bilirubin ≤ 1.5 time upper limit normal ( x ULN ) Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 x ULN ( ≤ 5.0 x ULN acceptable liver tumor involvement ) Serum Creatinine ≤ 1.5 x ULN PTINR/PTT ≤ 1.5 x ULN therapeutic range anticoagulation therapy Lymphoma : Acceptable liver , renal bone marrow function include follow : Absolute Neutrophil Count ≥ 1.0 x 109/L Platelets ≥ 50 x 109/L Bilirubin ≤ 1.5 time upper limit normal ( x ULN ) , ≤ 3 time ULN document hepatic involvement lymphoma , ≤ 5 time ULN history Gilbert 's disease Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3.0 x ULN ( ≤ 5.0 x ULN acceptable liver tumor involvement ) Serum Creatinine ≤ 1.5 x ULN PTINR/PTT ≤ 1.5 x ULN therapeutic range anticoagulation therapy Serum potassium within normal range Estimated life expectancy great 3 month Signed informed consent must obtain prior study specific procedure Exclusion Criteria Patients meet follow criterion eligible enroll trial : Prior treatment PXD101 Solid Tumor : Anticancer therapy include chemotherapy , radiotherapy , endocrine therapy , immunotherapy use investigational agent within last 4 week long period depend defined characteristic agent use ( e.g . 6 week mitomycin nitrosourea ) Lymphoma : No anticancer therapy within 2 week except Rituximab patient great three month unless evidence disease progression . Lymphoma patient relapse within 100 day autologous allogeneic transplantation . Serious concomitant systemic disorder ( eg , active infection ) , opinion investigator , would compromise safety patient compromise patient 's ability complete study . Presence metastatic disease , opinion investigator , would require palliative treatment within 4 week enrollment Symptomatic brain metastasis Significant cardiovascular disease include unstable angina pectoris , uncontrolled hypertension , congestive heart failure ( NYHA Class III IV ) relate primary cardiac disease , condition require antiarrhythmic therapy , ischemic severe valvular heart disease , myocardial infarction within 6 month prior trial entry A mark baseline prolongation QT/QTc interval , e.g. , repeat demonstration QTc interval &gt; 500 msec ; Long QT Syndrome ; require use concomitant medication PXD101 dosing day may cause Torsade de Pointes ( See Section 11.7 ) Altered mental status preclude understand informed consent process and/or completion necessary study Pregnant breastfeed woman Men woman childbearing age potential , willing use effective contraception Major surgery within last 4 week Known HIV positivity , safety patient population assess .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Adenosarcoma</keyword>
	<keyword>B-cell lymphoma</keyword>
	<keyword>belinostat</keyword>
	<keyword>bladder cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>Carcinoma , Small Cell</keyword>
	<keyword>Chondrosarcoma</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>Esophageal Neoplasms</keyword>
	<keyword>Fibrosarcoma</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>Hemangiosarcoma</keyword>
	<keyword>Hodgkins Disease</keyword>
	<keyword>kidney cancer</keyword>
	<keyword>Leiomyosarcoma</keyword>
	<keyword>Liposarcoma</keyword>
	<keyword>lung cancer</keyword>
	<keyword>lymphoma</keyword>
	<keyword>mesothelioma</keyword>
	<keyword>mesothelioma , cystic</keyword>
	<keyword>Mixed Tumor , Mesodermal</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Otorhinolaryngologic Neoplasms</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Parathyroid Neoplasms</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>sarcoma</keyword>
	<keyword>T-cell lymphoma</keyword>
	<keyword>thyroid cancer</keyword>
	<keyword>PXD101</keyword>
</DOC>